JP6009355B2 - Vap−1阻害剤、およびvap−1阻害剤の使用 - Google Patents
Vap−1阻害剤、およびvap−1阻害剤の使用 Download PDFInfo
- Publication number
- JP6009355B2 JP6009355B2 JP2012528399A JP2012528399A JP6009355B2 JP 6009355 B2 JP6009355 B2 JP 6009355B2 JP 2012528399 A JP2012528399 A JP 2012528399A JP 2012528399 A JP2012528399 A JP 2012528399A JP 6009355 B2 JP6009355 B2 JP 6009355B2
- Authority
- JP
- Japan
- Prior art keywords
- vap
- fibrosis
- seq
- inhibitor
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
- G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Description
本発明の他の目的、詳細及び効果は以下の図面、詳細な説明及び実施例から明らかになるものと思われる。
〔肝線維症のマウスモデルにおけるVAP−1阻害剤の効果〕
この検証の目的は、VAP−1阻害剤のマウスの線維性肝損傷に対する効果を評価することだった。
〔腎傷害のマウスモデルにおけるVAP−1阻害剤の腎保護効果〕
四塩化炭素に多く曝されると肝臓と腎臓の両方が損傷する。したがって、腎障害に対するVAP−1の効果を見るために、実施例1に記載されたCCl4が投与された動物の腎臓が採取・分析された。
〔COPDのマウスモデルにおけるVAP−1阻害剤の効果〕
タバコ煙によるCOPDのマウスモデルがCOPD治療におけるVAP−1阻害剤の効果を評価するために用いられた。
〔血管壁の新生内膜及び内側線維症に対するVAP−1阻害剤の効果〕
新生内膜及び内側肥厚はアテローム性動脈硬化症の進行における初期かつ重要な病気であり、最狭窄の重要な因子である。肥厚は血管壁の新生内膜及び中膜における線維性の変化を伴う。本検証では、安価なウェスタン飼料を与えられたApoE3ライデンマウスの大腿動脈におけるカフ誘発性新生内膜肥厚(カフ誘発性狭窄)に対する小分子SSAO阻害剤(モフェジリン、BTT−2089)の全身投与(連日腹腔内注射による)の効果を評価することにより、線維性疾患における阻害SSAOの役割を評価した。
〔肺線維症のマウスモデルにおけるVAP−1阻害剤の効果〕
ブレオマイシン誘発性肺線維症は、肺線維症を検証するための確立した再現可能なマウスモデルである。
〔糖尿病性腎疾患のマウスモデルにおけるVAP−1阻害剤の腎保護効果〕
糖尿病は進行性の腎線維症を伴う糖尿病性腎症(DN)を引き起こすことがあり、結果、機能する腎体積が減少する。腎線維症に対する抗VAP−1抗体及びSSAO阻害剤の効果を評価するに際し、十分に確立した糖尿病性腎疾患のDb/db糖尿病マウスモデルが採用された。
マイルド :グレード2、基質に占められる糸球体体積が25から50%
モデラート:グレード3、基質に占められる糸球体体積が50から75%
シビア :グレード4、基質に占められる糸球体体積が75から100%
〔糖尿病性腎症に対する抗線維症治療〕
糖尿病性腎症は最終ステージの腎疾患及び線維症(特に間質性線維症)に共通の原因であり、糖尿病の腎臓の主要な病理学的特徴である。臨床的検証により、VAP−1阻害剤が糖尿病の患者の腎症を低減し腎機能をもたせることが可能か否か判断可能である。
〔線維性疾患の診断マーカーとしてのVAP−1〕
本実施例では、免疫組織化学試験により、線維化中隔(fibrotic septa)がかなり高いレベルの肝硬変において肝VAP−1発現が増加することが分かった(図13から15)。多色共焦点顕微鏡検査により肝星細胞及び筋線維芽細胞におけるVAP−1発現が明らかにされた(図16)。培養されたヒト肝星細胞(HSCs)を用いて、体内HSCsによるsVAP−1の発現及び分泌が確認された。これらの結果は線維成長におけるVAP−1の潜在的な役割を示唆した。
Claims (3)
- 抗線維化剤として用いられるVAP−1阻害剤であって、
前記VAP−1阻害剤は、配列番号1から3からなる群から選択される1から3のCDRコンセンサス配列を有する完全ヒト抗VAP−1抗体であり、
前記抗体は、配列番号19に示される重鎖可変領域及び配列番号42に示される軽鎖可変領域を有するか、配列番号20に示される重鎖可変領域及び配列番号43に示される軽鎖可変領域を有するか、配列番号21に示される重鎖可変領域及び配列番号44に示される軽鎖可変領域を有するか、配列番号22に示される重鎖可変領域及び配列番号45に示される軽鎖可変領域を有するか、または配列番号23に示される重鎖可変領域及び配列番号46に示される軽鎖可変領域を有し、
前記VAP−1阻害剤は、肺線維症、糖尿病性腎症に起因するものを含む腎線維症、およびCOPDから選択される線維性疾患の治療に用いるためのものであるVAP−1阻害剤。 - 請求項1に記載のVAP−1阻害剤において、
前記抗体は、配列番号47で示される重鎖ポリペプチドと配列ID番号48で示される軽鎖ペプチドとを有する完全ヒト組み換え抗体である
ことを特徴とするVAP−1阻害剤。 - 前記線維性疾患を治療する薬を製造するための請求項1または請求項2に記載のVAP−1阻害剤の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24040209P | 2009-09-08 | 2009-09-08 | |
US61/240,402 | 2009-09-08 | ||
US32303210P | 2010-04-12 | 2010-04-12 | |
US61/323,032 | 2010-04-12 | ||
PCT/FI2010/050689 WO2011029996A1 (en) | 2009-09-08 | 2010-09-07 | Use of vap-1 inhibitors for treating fibrotic conditions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016003089A Division JP6290940B2 (ja) | 2009-09-08 | 2016-01-08 | 診断剤、完全ヒト抗vap−1抗体の使用、及びキット |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013503915A JP2013503915A (ja) | 2013-02-04 |
JP2013503915A5 JP2013503915A5 (ja) | 2016-03-31 |
JP6009355B2 true JP6009355B2 (ja) | 2016-10-19 |
Family
ID=43732037
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012528399A Expired - Fee Related JP6009355B2 (ja) | 2009-09-08 | 2010-09-07 | Vap−1阻害剤、およびvap−1阻害剤の使用 |
JP2016003089A Expired - Fee Related JP6290940B2 (ja) | 2009-09-08 | 2016-01-08 | 診断剤、完全ヒト抗vap−1抗体の使用、及びキット |
JP2018020789A Pending JP2018104445A (ja) | 2009-09-08 | 2018-02-08 | 線維性疾患治療のためのvap−1阻害剤の使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016003089A Expired - Fee Related JP6290940B2 (ja) | 2009-09-08 | 2016-01-08 | 診断剤、完全ヒト抗vap−1抗体の使用、及びキット |
JP2018020789A Pending JP2018104445A (ja) | 2009-09-08 | 2018-02-08 | 線維性疾患治療のためのvap−1阻害剤の使用 |
Country Status (26)
Country | Link |
---|---|
US (2) | US9795671B2 (ja) |
EP (1) | EP2475387B1 (ja) |
JP (3) | JP6009355B2 (ja) |
KR (2) | KR20180026808A (ja) |
CN (2) | CN102740886A (ja) |
AU (1) | AU2010294123B2 (ja) |
CA (1) | CA2773218C (ja) |
CY (1) | CY1119867T1 (ja) |
DK (1) | DK2475387T3 (ja) |
ES (1) | ES2657943T3 (ja) |
HR (1) | HRP20180131T1 (ja) |
HU (1) | HUE035890T2 (ja) |
IL (1) | IL218535A (ja) |
LT (1) | LT2475387T (ja) |
ME (1) | ME02999B (ja) |
NO (1) | NO2475387T3 (ja) |
NZ (3) | NZ616432A (ja) |
PL (1) | PL2475387T3 (ja) |
PT (1) | PT2475387T (ja) |
RS (1) | RS56809B1 (ja) |
RU (2) | RU2667963C1 (ja) |
SG (1) | SG179012A1 (ja) |
SI (1) | SI2475387T1 (ja) |
UA (1) | UA112154C2 (ja) |
WO (1) | WO2011029996A1 (ja) |
ZA (1) | ZA201202515B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018104445A (ja) * | 2009-09-08 | 2018-07-05 | バイオティ セラピーズ コーポレイション | 線維性疾患治療のためのvap−1阻害剤の使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5953035B2 (ja) * | 2011-11-28 | 2016-07-13 | 学校法人慶應義塾 | 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム |
PT2844637T (pt) | 2012-05-02 | 2018-04-17 | Boehringer Ingelheim Int | Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações |
WO2014024820A1 (ja) * | 2012-08-06 | 2014-02-13 | 塩野義製薬株式会社 | 新規慢性腎臓病治療用医薬組成物及び新規慢性腎臓病治療薬のスクリーニング方法 |
KR102205845B1 (ko) | 2013-10-28 | 2021-01-22 | 삼성전자주식회사 | 입자에 기반한 모델링 방법 및 장치 |
WO2015189534A1 (en) * | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
JP2018080114A (ja) * | 2015-05-29 | 2018-05-24 | 株式会社アールテック・ウエノ | 抗ヒトvap−1モノクローナル抗体 |
EP3645039A4 (en) * | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS |
WO2023164548A1 (en) * | 2022-02-23 | 2023-08-31 | Yale University | Il-6 inhibitor as treatment for nephropathy |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997854A (en) * | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US5580780A (en) | 1992-06-09 | 1996-12-03 | Jalkanen; Sirpa | Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies |
RU2204838C2 (ru) * | 1997-05-23 | 2003-05-20 | Байотай Терапис Лтд. | Сосудистый белок - 1 адгезии, обладающий аминооксидазной активностью |
RU2003103286A (ru) | 2000-07-05 | 2004-08-20 | Байотай Терапис Корпорейшн (Fi) | Ингибиторы медьсодержащих аминооксидаз |
AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
EP1353676A4 (en) | 2000-12-29 | 2006-05-31 | Alteon Inc | METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS |
US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
FI20020807A0 (fi) * | 2002-04-29 | 2002-04-29 | Biotie Therapies Oyj | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita |
CA2514573A1 (en) | 2003-01-27 | 2004-08-12 | Astellas Pharma Inc. | Thiazole derivatives and their use as vap-1 inhibitors |
US20060229346A1 (en) | 2003-03-31 | 2006-10-12 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
WO2005014530A2 (en) | 2003-08-08 | 2005-02-17 | La Jolla Pharmaceutical Co. | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases |
WO2005072738A1 (en) | 2004-01-30 | 2005-08-11 | Faron Pharmaceuticals Oy | Compositions useful especially for treatment or prevention of metabolic syndrome |
FI20040270A0 (fi) | 2004-02-20 | 2004-02-20 | Biotie Therapies Oyj | Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset |
CA2556914A1 (en) | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
CN1933833B (zh) | 2004-03-18 | 2011-09-07 | 株式会社·R-技术上野 | 含有噻唑衍生物的含水组合物 |
CA2575411A1 (en) * | 2004-07-27 | 2006-02-02 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
AU2005268781A1 (en) * | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
CA2579889A1 (en) | 2004-09-09 | 2006-03-16 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
WO2006094201A2 (en) * | 2005-03-02 | 2006-09-08 | La Jolla Pharmaceutical Company | Semicarbazide-sensitive amide oxidase inhibitors |
WO2007005737A2 (en) | 2005-07-01 | 2007-01-11 | Case Western Reserve University | Amine oxidase inhibitors |
US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
FI20075278A0 (fi) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
WO2009055002A1 (en) | 2007-10-24 | 2009-04-30 | La Jolla Pharmaceutical Company | Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (ssao) (vascular adhesion protein, vap-1) |
SG186008A1 (en) * | 2007-11-21 | 2012-12-28 | Pharmaxis Ltd | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
TWI437986B (zh) * | 2008-01-31 | 2014-05-21 | R Tech Ueno Ltd | 噻唑衍生物及使用該衍生物作為vap-1抑制劑之用途 |
TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
HUP0800498A2 (en) | 2008-08-06 | 2010-03-29 | Semmelweis Egyetem | Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level |
US8536210B2 (en) | 2008-09-11 | 2013-09-17 | Semmelweis Egyetem | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases |
US8263616B2 (en) | 2008-09-16 | 2012-09-11 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
-
2010
- 2010-07-09 UA UAA201204308A patent/UA112154C2/uk unknown
- 2010-09-07 DK DK10815041.8T patent/DK2475387T3/en active
- 2010-09-07 CN CN2010800503481A patent/CN102740886A/zh active Pending
- 2010-09-07 RS RS20180101A patent/RS56809B1/sr unknown
- 2010-09-07 NO NO10815041A patent/NO2475387T3/no unknown
- 2010-09-07 PL PL10815041T patent/PL2475387T3/pl unknown
- 2010-09-07 ES ES10815041.8T patent/ES2657943T3/es active Active
- 2010-09-07 HU HUE10815041A patent/HUE035890T2/en unknown
- 2010-09-07 NZ NZ61643210A patent/NZ616432A/en not_active IP Right Cessation
- 2010-09-07 CN CN201710879422.4A patent/CN107661500A/zh active Pending
- 2010-09-07 WO PCT/FI2010/050689 patent/WO2011029996A1/en active Application Filing
- 2010-09-07 KR KR1020187006357A patent/KR20180026808A/ko not_active IP Right Cessation
- 2010-09-07 PT PT108150418T patent/PT2475387T/pt unknown
- 2010-09-07 CA CA2773218A patent/CA2773218C/en not_active Expired - Fee Related
- 2010-09-07 KR KR1020127009075A patent/KR101837117B1/ko active IP Right Grant
- 2010-09-07 SG SG2012015772A patent/SG179012A1/en unknown
- 2010-09-07 NZ NZ598920A patent/NZ598920A/en not_active IP Right Cessation
- 2010-09-07 AU AU2010294123A patent/AU2010294123B2/en not_active Ceased
- 2010-09-07 NZ NZ706740A patent/NZ706740A/en not_active IP Right Cessation
- 2010-09-07 EP EP10815041.8A patent/EP2475387B1/en active Active
- 2010-09-07 RU RU2016107043A patent/RU2667963C1/ru active
- 2010-09-07 JP JP2012528399A patent/JP6009355B2/ja not_active Expired - Fee Related
- 2010-09-07 LT LTEP10815041.8T patent/LT2475387T/lt unknown
- 2010-09-07 SI SI201031624T patent/SI2475387T1/en unknown
- 2010-09-07 US US13/395,029 patent/US9795671B2/en active Active
- 2010-09-07 RU RU2012113561/15A patent/RU2580626C2/ru active
-
2012
- 2012-03-07 IL IL218535A patent/IL218535A/en active IP Right Grant
- 2012-04-05 ZA ZA2012/02515A patent/ZA201202515B/en unknown
-
2016
- 2016-01-08 JP JP2016003089A patent/JP6290940B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-21 US US15/711,828 patent/US10576148B2/en not_active Expired - Fee Related
-
2018
- 2018-01-23 HR HRP20180131TT patent/HRP20180131T1/hr unknown
- 2018-01-31 CY CY20181100116T patent/CY1119867T1/el unknown
- 2018-02-08 JP JP2018020789A patent/JP2018104445A/ja active Pending
- 2018-02-28 ME MEP-2018-21A patent/ME02999B/me unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018104445A (ja) * | 2009-09-08 | 2018-07-05 | バイオティ セラピーズ コーポレイション | 線維性疾患治療のためのvap−1阻害剤の使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6290940B2 (ja) | 診断剤、完全ヒト抗vap−1抗体の使用、及びキット | |
Zhou et al. | Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system | |
Chodavarapu et al. | Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion | |
Cosgrove et al. | Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice | |
Ma et al. | Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1 | |
JP6955443B2 (ja) | 肺動脈性肺高血圧症の処置に関する方法および組成物 | |
JP2016536332A5 (ja) | ||
US20150010536A1 (en) | Humanized PAI-1 Antibodies and Uses Thereof | |
JP6239635B2 (ja) | 血管石灰化の誘導因子であるソルチリン1 | |
US10633455B2 (en) | Method for treating and diagnosing disease using inhibitors of goodpasture antigen binding protein | |
WO2023174193A1 (zh) | Septin4突变基因及其制药用途 | |
JP2008512463A (ja) | マトリックスメタロプロテイナーゼ−12に関連する糸球体基底膜疾患の治療 | |
Navas‐Madroñal et al. | Targeting mitochondrial stress with Szeto‐Schiller 31 prevents experimental abdominal aortic aneurysm: Crosstalk with endoplasmic reticulum stress | |
TWI594764B (zh) | 治療用途 | |
WO2022064069A1 (en) | Mmp-9 as a predictive marker of chronic allograft dysfunction | |
Veitch | Late Interventions in SNXRats Reveal a Disconnect between GFR and Proteinuria | |
Kraikriangsri et al. | Case Review of lgG4-Related Disease Patient with Combined Tubulointerstitial Nephritis and Membranous Nephropathy Coexisting with Cholangiocarcinoma: Case Report. | |
Donahue et al. | Renal Insufficiency and the Impact of Contrast Agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150324 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160108 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160108 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160914 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6009355 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |